Protagonist Therapeutics' CEO on its hepcidin memetic at #ASH23 and oral IL23 program in I&I

blonca9
Dec 10, 2023
1 min read

Dinesh Patel describes the science behind Protagonist's polycythemia vera program and how the company is developing oral peptides, starting with IL23.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Protagonist Therapeutics' CEO on its hepcidin memetic at #ASH23 and oral IL23 program in I&I

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight